04212018Headline:

New York, New York

HomeNew YorkNew York

Roopal Luhana

New Onglyza Lawsuit Claims Drug Led to Heart Failure

In late February 2018, an Ohio woman, as representative of a male family member, filed a new Onglyza lawsuit in the U.S. District Court for the Southern District of Ohio. This case now joins a number of other similar cases […]

Roopal Luhana

North Carolina Woman Claims Kombiglyze XR Caused Congestive Heart Failure

On January 23, 2018, a North Carolina woman filed a new Kombiglyze XR (saxagliptin and metformin) lawsuit against manufacturers Bristol-Myers Squibb and AstraZeneca. She claims that after taking the diabetes medication, she suffered serious injuries that required hospitalization. She filed […]

Roopal Luhana

Illinois Man Blames Onglyza for his Heart Failure

On January 9, 2018, an Illinois man filed a new Onglyza lawsuit in the U.S. District Court for the Central District of Illinois.  He claims that after taking the diabetes medication, he suffered serious injuries.  He seeks in excess of […]

Eric T. Chaffin

Studies Show Tasigna Increases Risk of Atherosclerosis

Tasigna (nilotinib) is a drug manufactured by Novartis to treat chronic myelogenous leukemia (CML). The FDA approved it for this use in 2007, but since then, there have been several studies that have linked the medication with an increased risk […]

Roopal Luhana

FDA Announces Limbrel Recall

On January 28, 2018, the FDA alerted consumers and their healthcare providers to the fact that Primus Pharmaceuticals had implemented a recall of all Limbrel products due to rare but potentially serious health risks. Primus is notifying distributors and is […]

Roopal Luhana

JPML Orders Transfer of Onglyza Lawsuits to Eastern District of Kentucky

On February 2, 2018, the U.S. Judicial Panel on Multidistrict Litigation (“JPML” or “panel”) ordered that all federally-filed Onglyza (saxagliptin) lawsuits be centralized in the Eastern District of Kentucky.  That means a total of 84 cases pending in over 26 […]

Roopal Luhana

FDA Warns Customers to Stop Taking Limbrel for Arthritis

On December 5, 2017, the FDA released a safety advisory notifying doctors and patients of potential health hazards associated with Limbrel capsules. Limbrel was approved as a “medical food” that is intended to help manage the inflammation associated with osteoarthritis. […]

Roopal Luhana

Study Links E-Cigarettes to Birth Defects

So-called “popcorn lung” is a serious lung disease that causes inflammation and scarring in the airways and eventually leads to permanent lung damage. The disease was so-named because back in the 1990s, an abnormally large number of microwave popcorn factory […]

Eric T. Chaffin

Will the JPML Approve Consolidation of Onglyza Lawsuits?

If you’ve filed an Onglyza lawsuit, or if you’re thinking about it, mark January 25, 2018 on your calendar. That is the day that the U.S. Judicial Panel on Multidistrict Litigation will be hearing arguments about whether to consolidate all […]

Roopal Luhana

J&J Seeking to Expand Use of Xarelto Despite Side Effects

More than 20,500 Xarelto lawsuits are pending in consolidated litigation in the U.S. District Court for the Eastern District of Louisiana, and another 1,400 are pending in a mass tort in Philadelphia. Plaintiffs claim that after taking the blood-thinning medication, […]